The development of molecularly targeted therapies such as the BRAFi vemurafenib or dabrafenib3,4 and especially the combined BRAF and MEK inhibition improved the prognosis for BRAF-mutated metastatic melanoma patients5. This evidence concerns the gene MAP2K7 and metastatic melanoma.